Microneedle‐Assisted Transdermal Delivery of 2D Bimetallic Metal–Organic Framework Nanosheet‐Based Cascade Biocatalysts for Enhanced Catalytic Therapy of Melanoma

Current conventional treatments for malignant melanoma still face limitations, especially low therapeutic efficacy and serious side effects, and more effective strategies are urgently needed to develop them. Delivering biocatalysts into tumors to efficiently trigger in situ cascade reactions has shown huge potential in producing more therapeutic species or generating stronger tumoricidal effects for augmented tumor therapy. Recently, ultrathin 2D metal–organic framework (MOF) nanosheets have acquired great interest in biocatalysis owing to their large surface areas and abundant accessible active catalytic sites. Herein, an enhanced catalytic therapeutic strategy against melanoma is developed by biocompatible microneedle (MN)‐assisted transdermal delivery of a 2D bimetallic MOF nanosheet‐based cascade biocatalyst (Cu‐TCPP(Fe)@GOD). Profiting from the constructed dissolving MN system, the loaded Cu‐TCPP(Fe)@GOD hybrid nanosheets can be accurately delivered into the melanoma sites through skin barriers, and subsequently, trigger the specific cascade catalytic reactions in response to the acidic tumor microenvironment to effectively generate highly toxic hydroxyl radical (•OH) and deplete glucose nutrient for inducing the death of melanoma cells. The ultimate results prove the high melanoma inhibition effect and biosafety of such therapeutic modality, exhibiting a new and promising strategy to conquer malignant melanoma. A transdermal microneedle system loaded with a 2D bimetallic metal–organic framework nanosheet‐based cascade biocatalyst is developed for enhanced catalytic therapy of malignant melanoma by triggering the in situ cascade catalytic reactions within the tumor microenvironments to effectively generate highly toxic hydroxyl radical (•OH) and deplete glucose nutrient.